Please login to the form below

Not currently logged in
Email:
Password:

Sobi names Holly May VP of sales and marketing, US

She will work with the biopharma’s commercial and patient access teams

Holly MayRare disease firm Sobi has appointed Holly May as its new vice president of sales and marketing for the US.

May’s new role will see her lead the biopharma’s commercial team in bringing Sobi’s medicines to the country.

She will also collaborate with the operations and patient access team to ensure the medicines are accessible to as many appropriate patients and she will support the launch of new products in the US.

May said: “I have been privileged to work in the rare disease field, leading commercial teams in providing education to patients, caregivers and physicians around important rare disease issues.

“I look forward to applying my expertise to help Sobi bring its existing and future products to patients who need them.”

May has had more than 20 years’ experience in biopharmaceutical sales and marketing, with her most recent role serving as head of US marketing for Fabry disease and lysosmal storage disorders at Sanofi Genzyme.

Prior to her 17-year career at Sanofi, May held various sales positions at DuPont Pharmaceuticals and Endo.

Rami Levin, president of Sobi, North America, said: “As we look to increase our footprint specifically in North America, where more than 33 million patients are estimated to suffer from a rare disease, Holly’s experience will be incredibly valuable.”

30th January 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

Dimitri Azzopardi
Case-study for thalassaemia: Dimitri Azzopardi
An in-depth look at beta thalassaemia for Rare Disease Day...
Delivering change through better rare disease communications
OPEN Health’s Richard Jones, Gemma Allen and Charlotte Richards discuss how pharma can utilise tools, channels and stakeholders to deliver change and enable better outcomes....
Interim analysis clinical trials
Assessing the value of interim analyses in clinical trials
Why its important and when its needed...

Infographics